Katharina Dendl

Mrs. Katharina Dendl


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Radiology
Verified
Journal Article
Closed access
YMYuriko Mori
Yuriko Mori
KDKatharina Dendl
Katharina Dendl
JCJens Cardinale
Jens Cardinale
CKClemens Kratochwil
Clemens Kratochwil
FGFrederik L. Giesel
Frederik L. Giesel
UHUwe Haberkorn
Uwe Haberkorn
Gallium 68–labeled fibroblast activation protein inhibitor PET is an oncologic imaging strategy based on the molecular targeting of fibroblast activation protein highly expressed in the stroma of e... Gallium 68 (68Ga)–labeled fibroblast activation protein (FAP) inhibitor (FAPI) PET is based on the molecular targeting of the FAP, which is known to be highly expressed in the major cell population...

30 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KDKatharina Dendl
Katharina Dendl
SKStefan Alexander Körber
Stefan Alexander Körber
CKClemens Kratochwil
Clemens Kratochwil
JCJens Cardinale
Jens Cardinale
RFRebecca Finck
Rebecca Finck
Frederik L. GieselFrederik L. Giesel
Frederik L. Giesel
A fibroblast activation protein (FAP) is an atypical type II transmembrane serine protease with both endopeptidase and post-proline dipeptidyl peptidase activity. FAP is overexpressed in cancer-associated fibroblasts (CAFs), which are found in most epithelial tumors. CAFs have been implicated in promoting tumor cell invasion, angiogenesis and growth and their presence correlates with a poor prognosis. However, FAP can generally be found during the remodeling of the extracellular matrix and therefore can be detected in wound healing and benign diseases. For instance, chronic inflammation, arthritis, fibrosis and ischemic heart tissue after a myocardial infarction are FAP-positive diseases. Therefore, quinoline-based FAP inhibitors (FAPIs) bind with a high affinity not only to tumors but also to a variety of benign pathologic processes. When these inhibitors are radiolabeled with positron emitting radioisotopes, they provide new diagnostic and prognostic tools as well as insights into the role of the microenvironment in a disease. In this respect, they deliver additional information beyond what is afforded by conventional FDG PET scans that typically report on glucose uptake. Thus, FAP ligands are considered to be highly promising novel tracers that offer a new diagnostic and theranostic potential in a variety of diseases.

13 July 2022 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
KDKatharina Dendl
Katharina Dendl
SKStefan Alexander Körber
Stefan Alexander Körber
KTKatharina Tamburini
Katharina Tamburini
YMYuriko Mori
Yuriko Mori
JCJens Cardinale
Jens Cardinale
Frederik L. GieselFrederik L. Giesel
Frederik L. Giesel

29 May 2023 in PET Clinics
Verified
Journal Article
Closed access
KDKatharina Dendl
Katharina Dendl
SKStefan A. Koerber
Stefan A. Koerber
TWTadashi Watabe
Tadashi Watabe
UHUwe Haberkorn
Uwe Haberkorn
FGFrederik L. Giesel
Frederik L. Giesel

28 July 2021 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
KDKatharina Dendl
Katharina Dendl
AMAndreas Merkel
Andreas Merkel
CKClemens Kratochwil
Clemens Kratochwil
PCPeter L. Md Choyke
Peter L. Md Choyke
CKChristian Kleist
Christian Kleist
FGFrederik L. Md Giesel
Frederik L. Md Giesel
Prostate-specific membrane antigen (PSMA) PET/CT is a highly reliable nuclear tracer for diagnostic imaging of prostate cancer. However, PSMA is also expressed by some nonprostatic tissues such as benign tumors, inflammatory processes, and malignant neoplasms. This case presents a patient with prostate cancer and follicular lymphoma undergoing PSMA PET/CT. Remarkably, both tumor entities were clearly detected in the scan. Yet, the 2 malignancies demonstrated rather different ranges in terms of SUVmax uptake values and therefore still enabled precise and accurate discrimination of prostate cancer and follicular lymphoma.

23 August 2022 in Molecular Imaging and Biology
Verified
Journal Article
Open access
PDF file
SKStefan Alexander Körber
Stefan Alexander Körber
RKR. C. Kroener
R. C. Kroener
KDKatharina Dendl
Katharina Dendl
CKClemens Kratochwil
Clemens Kratochwil
CFC. A. Fink
C. A. Fink
Frederik L. GieselFrederik L. Giesel
Frederik L. Giesel
Purpose: Due to limited imaging options, the visualization of a local relapse of prostate cancer used to pose a considerable challenge. However, since the integration of 18F-PSMA-1007-PET/CT into the clinic, a relapsed tumor can now easily be detected by hybrid imaging. The present study aimed to evaluate and map the allocate relapse in a large cohort of prostate cancer patients focusing on individual patient management conclusions for radiation therapy. Procedures: The current study included 135 men with prostate cancer after primary treatment who underwent 18F-PSMA-1007-PET/CT due to biochemical relapse detecting a local relapse. Imaging data were reassessed and analyzed with regard to relapse locations. For the correlation of tumor foci with clinical data, we used binary logistic regression models as well as the Kruskal–Wallis test and Mann–Whitney test. Results: In total, 69.6% of all patients (mean age: 65 years) underwent prostatectomy while 30.4% underwent radiation therapy. PET imaging detected most frequently a unifocal relapse (72.6%). There was a statistically significantly higher rate of ipsilateral cases among the relapsed tumors. Comparing both treatment approaches, tumors relapsed most commonly within the posterior region after surgery and transition/peripheral zone after radiation therapy, respectively. Conclusions: The present study confirms that 18F-PSMA-1007-PET/CT is highly suitable for the localization and allocation of a local relapse in patients with prostate cancer. The data enable further optimizing dose prescriptions and target volume delineations of radiation therapy in the future.